ArticleCancer immunology, immunotherapy : CII2022

Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.

Jifang Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.